Immunovia AB (OSTO:IMMNOV)
kr 0.618 -0.01 (-1.59%) Market Cap: 104.88 Mil Enterprise Value: 76.83 Mil PE Ratio: 0 PB Ratio: 2.91 GF Score: 44/100

Immunovia AB (publ) - Special Call Transcript

Dec 17, 2020 / 02:00PM GMT
Release Date Price: kr54.96 (-3.09%)
Patrik Dahlen;publ;CEO
Immunovia AB

()-

Good afternoon, everyone. My name is Patrik Dahlen. I am the CEO of Immunovia, and I will be the moderator of this webinar. A very warm welcome to all of you to this Immunovia webinar.

With me on this webinar call are Dr. Thomas King, who is our Medical Director; Dr. Linda Mellby, who is our Vice President of R&D; and Dr. Laura Chirica, who is our Chief Commercial Officer.

This is the third webinar in a series of webinars that we have run since the beginning of this summer. Today's webinar is called IMMray PanCan-d Verification Study and Clinical Use. The agenda for the webinar is positioning of IMMray PanCan-d in clinical practice, this will be presented by Dr. King; the verification study versus clinical practice, this will be presented by Linda Mellby; and the voice of the pancreatic cancer experts about IMMray PanCan-d clinical utility, and this will be presented by Laura, who is our Chief Commercial Officer.

Please remember that at the end of the webinar, you will have a chance to ask questions.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot